LLY

714.93

-0.22%↓

JNJ

153.31

+0.27%↑

ABBV

183.82

+0.38%↑

NVO

67.42

-1.29%↓

UNH

294.81

-0.72%↓

LLY

714.93

-0.22%↓

JNJ

153.31

+0.27%↑

ABBV

183.82

+0.38%↑

NVO

67.42

-1.29%↓

UNH

294.81

-0.72%↓

LLY

714.93

-0.22%↓

JNJ

153.31

+0.27%↑

ABBV

183.82

+0.38%↑

NVO

67.42

-1.29%↓

UNH

294.81

-0.72%↓

LLY

714.93

-0.22%↓

JNJ

153.31

+0.27%↑

ABBV

183.82

+0.38%↑

NVO

67.42

-1.29%↓

UNH

294.81

-0.72%↓

LLY

714.93

-0.22%↓

JNJ

153.31

+0.27%↑

ABBV

183.82

+0.38%↑

NVO

67.42

-1.29%↓

UNH

294.81

-0.72%↓

Search

Celldex Therapeutics Inc

Gesloten

SectorGezondheidszorg

20.26 -0.69

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

19.48

Max

20.49

Belangrijke statistieken

By Trading Economics

Inkomsten

-6.7M

-54M

Verkoop

-480K

695K

EPS

-0.81

Winstmarge

-7,740.432

Werknemers

186

EBITDA

-3.9M

-55M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+185.71% upside

Dividenden

By Dow Jones

Volgende Winsten

6 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

41M

1.4B

Vorige openingsprijs

20.95

Vorige sluitingsprijs

20.26

Nieuwssentiment

By Acuity

50%

50%

174 / 382 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

Celldex Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

22 mei 2025, 23:48 UTC

Populaire aandelen

Stocks to Watch: Deckers Outdoor, Intuit, Ross Stores, Lightbridge, NuScale Power, Centrus Energy

22 mei 2025, 23:07 UTC

Top Nieuws

Fortescue Energy CEO to Resign in Executive Overhaul

22 mei 2025, 23:03 UTC

Belangrijke Marktbewegers

Nuclear-Industry Stocks Get Boost After Report Says Trump Will Sign Orders to Jumpstart Field

22 mei 2025, 23:59 UTC

Marktinformatie

Gold Edges Higher, Supported by Lingering Worries Over U.S. Deficits -- Market Talk

22 mei 2025, 23:45 UTC

Marktinformatie

Nikkei May Trade in Range as Uncertainty Over Tariffs Continues -- Market Talk

22 mei 2025, 23:45 UTC

Marktinformatie

Global Equities Roundup: Market Talk

22 mei 2025, 23:23 UTC

Marktinformatie

Global Energy Roundup: Market Talk

22 mei 2025, 23:23 UTC

Marktinformatie

Fortescue Iron Bridge Delay Disappoints; Executive Changes Welcomed -- Market Talk

22 mei 2025, 23:12 UTC

Top Nieuws

Supreme Court Lets Trump Fire Agency Officials, but Moves to Protect Fed -- WSJ

22 mei 2025, 21:54 UTC

Top Nieuws

Global Finance Officials Gloss Over Trade Tensions At G-7 Summit -- WSJ

22 mei 2025, 20:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

22 mei 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

22 mei 2025, 20:46 UTC

Acquisities, Fusies, Overnames

Alcon and Lensar Receive FTC Requests for Additional Information About Merger

22 mei 2025, 20:39 UTC

Winsten

Tesla's Emissions Credits Are at Risk After Senate's California Vote -- Barrons.com

22 mei 2025, 20:36 UTC

Top Nieuws

Antitrust Cops Say BlackRock, Other Fund Giants May Have Harmed Energy Competition -- 4th Update

22 mei 2025, 20:36 UTC

Top Nieuws
Winsten

Workday Logs Higher 1Q Revenue, Backs Outlook; Initiates $1B Buyback Program

22 mei 2025, 20:32 UTC

Top Nieuws
Winsten

Intuit Stock Rises After Earnings Grew More than Expected In Latest Tax Season -- Barrons.com

22 mei 2025, 20:27 UTC

Top Nieuws

Trump's 'Big, Beautiful Bill' Heads to Senate, Where New Fights Loom -- WSJ

22 mei 2025, 20:20 UTC

Top Nieuws

Bond Market Shows Signs of Stabilizing; Nasdaq Rises -- WSJ

22 mei 2025, 20:17 UTC

Top Nieuws

The Deficit Is Unsettling Bond Traders. Here's How That Affects the Economy. -- 2nd Update

22 mei 2025, 20:16 UTC

Winsten

Intchains Group 1Q Rev $18.2M >ICG

22 mei 2025, 20:15 UTC

Top Nieuws

Bond Market Shows Signs of Stabilizing; Nasdaq Rises -- WSJ

22 mei 2025, 20:08 UTC

Top Nieuws
Winsten

Intuit Stock Rises After Earnings Grew More than Expected In Latest Tax Season -- Barrons.com

22 mei 2025, 20:05 UTC

Top Nieuws

Intuit Seeing Stable Environment for Consumers, Businesses While Tariffs Play Out

22 mei 2025, 20:04 UTC

Winsten

Workday Sees FY26 Subscription Revenue $8.8B >WDAY

22 mei 2025, 20:04 UTC

Winsten

Workday Sees 2Q Subscription Revenue $2.16B >WDAY

22 mei 2025, 20:01 UTC

Winsten

Intuit Sees FY25 EPS $13.19-EPS $12.24 >INTU

22 mei 2025, 20:01 UTC

Winsten

Workday 1Q Net $68M >WDAY

22 mei 2025, 20:01 UTC

Winsten

Workday 1Q EPS 25c >WDAY

22 mei 2025, 20:01 UTC

Winsten

Workday 1Q Adj EPS $2.23 >WDAY

Peer Vergelijking

Prijswijziging

Celldex Therapeutics Inc Prognose

Koersdoel

By TipRanks

185.71% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 58.2 USD  185.71%

Hoogste 80 USD

Laagste 36 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Celldex Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

11 ratings

10

Buy

1

Hold

0

Sell

Technische score

By Trading Central

18.91 / 20.63Steun & Weerstand

Korte Termijn

Weak Bullish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

174 / 382 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.